http://www.streetinsider.com Latest StreetInsider.com News Articles en-us Copyright 2026, StreetInsider.com rss@streetinsider.com (SI RSS) rss@streetinsider.com (SI RSS) Thu, 16 Jul 2026 06:35:40 -0400 http://blogs.law.harvard.edu/tech/rss http://www.streetinsider.com/images/rss_logo.gif http://www.streetinsider.com 143 28 0 1 2 3 21 22 23 Saturday Sunday http://www.streetinsider.com/Corporate+News/Compass+Pathways+study+finds+COMP360+support+differs+from+psychotherapy/26776217.html <p>Compass Pathways plc (Nasdaq: CMPS) has published a post-hoc analysis in the <em>Journal of Psychopharmacology</em> examining the nature of monitoring and support provided during treatment administration sessions in an open-label Phase 2 study of its investigational COMP360 synthetic psilocybin treatment in patients with post-traumatic stress disorder (PTSD).</p><p>The analysis found that 78% of administration sessions were spent in silence. Interactions between participants and support providers were described as minimal and non-directive, with patients linking support primarily to physical presence, reassurance, and validation. The study concluded that these interactions are distinct from conventional psychotherapy or trauma-focused psychological treatments.</p><p>Support providers in Compass trials http://www.streetinsider.com/Corporate+News/Compass+Pathways+study+finds+COMP360+support+differs+from+psychotherapy/26776217.html Thu, 16 Jul 2026 06:35:40 -0400 CMPS http://www.streetinsider.com/FDA/Compass+Pathways+study+finds+COMP360+support+differs+from+psychotherapy/26776217.html <p>Compass Pathways plc (Nasdaq: CMPS) has published a post-hoc analysis in the <em>Journal of Psychopharmacology</em> examining the nature of monitoring and support provided during treatment administration sessions in an open-label Phase 2 study of its investigational COMP360 synthetic psilocybin treatment in patients with post-traumatic stress disorder (PTSD).</p><p>The analysis found that 78% of administration sessions were spent in silence. Interactions between participants and support providers were described as minimal and non-directive, with patients linking support primarily to physical presence, reassurance, and validation. The study concluded that these interactions are distinct from conventional psychotherapy or trauma-focused psychological treatments.</p><p>Support providers in Compass trials http://www.streetinsider.com/FDA/Compass+Pathways+study+finds+COMP360+support+differs+from+psychotherapy/26776217.html Thu, 16 Jul 2026 06:35:40 -0400 CMPS http://www.streetinsider.com/Press+Releases/Compass+Pathways+Announces+Publication+of+Post-Hoc+Analysis+Demonstrating+Distinction+of+COMP360+Trial+Monitoring+%26amp%3B+Support+from+Psychotherapy/26776210.html <ul class="bwlistdisc"> <li> <b>Post-hoc analysis of support methods used in an open-label Phase 2 COMP360 study showed monitoring and support provided during treatment administration sessions were minimal, non-directive and distinct from conventional conceptions of psychotherapy</b> </li> </ul><ul class="bwlistdisc"> <li> <b>Findings published in the <a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fjournals.sagepub.com%2Fdoi%2F10.1177%2F02698811261464988&amp;esheet=54570833&amp;newsitemid=20260716248636&amp;lan=en-US&amp;anchor=Journal+of+Psychopharmacology&amp;index=1&amp;md5=19442c914139081cfdfd97e83c2c5725" shape="rect">Journal of Psychopharmacology</a></b> </li> </ul> <p> LONDON &amp; NEW YORK--(BUSINESS WIRE)-- Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental health, today announced the publication of a post-hoc analysis of support methods used in an open-label Phase 2 study of investigational COMP360 synthetic psilocybin treatment in patients with post-traumatic stress disorder http://www.streetinsider.com/Press+Releases/Compass+Pathways+Announces+Publication+of+Post-Hoc+Analysis+Demonstrating+Distinction+of+COMP360+Trial+Monitoring+%26amp%3B+Support+from+Psychotherapy/26776210.html Thu, 16 Jul 2026 06:35:00 -0400 A.50216310 CMPS O.29029261 O.47928049 http://www.streetinsider.com/Press+Releases/Compass+Pathways+Announces+Publication+of+Post-Hoc+Analysis+Demonstrating+Distinction+of+COMP360+Trial+Monitoring+%26amp%3B+Support+from+Psychotherapy/26776210.html <ul class="bwlistdisc"> <li> <b>Post-hoc analysis of support methods used in an open-label Phase 2 COMP360 study showed monitoring and support provided during treatment administration sessions were minimal, non-directive and distinct from conventional conceptions of psychotherapy</b> </li> </ul><ul class="bwlistdisc"> <li> <b>Findings published in the <a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fjournals.sagepub.com%2Fdoi%2F10.1177%2F02698811261464988&amp;esheet=54570833&amp;newsitemid=20260716248636&amp;lan=en-US&amp;anchor=Journal+of+Psychopharmacology&amp;index=1&amp;md5=19442c914139081cfdfd97e83c2c5725" shape="rect">Journal of Psychopharmacology</a></b> </li> </ul> <p> LONDON &amp; NEW YORK--(BUSINESS WIRE)-- Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental health, today announced the publication of a post-hoc analysis of support methods used in an open-label Phase 2 study of investigational COMP360 synthetic psilocybin treatment in patients with post-traumatic stress disorder http://www.streetinsider.com/Press+Releases/Compass+Pathways+Announces+Publication+of+Post-Hoc+Analysis+Demonstrating+Distinction+of+COMP360+Trial+Monitoring+%26amp%3B+Support+from+Psychotherapy/26776210.html Thu, 16 Jul 2026 06:35:00 -0400 A.50216310 CMPS O.29029261 O.47928049 http://www.streetinsider.com/Press+Releases/Compass+Pathways+Announces+Publication+of+Post-Hoc+Analysis+Demonstrating+Distinction+of+COMP360+Trial+Monitoring+%26amp%3B+Support+from+Psychotherapy/26776210.html <ul class="bwlistdisc"> <li> <b>Post-hoc analysis of support methods used in an open-label Phase 2 COMP360 study showed monitoring and support provided during treatment administration sessions were minimal, non-directive and distinct from conventional conceptions of psychotherapy</b> </li> </ul><ul class="bwlistdisc"> <li> <b>Findings published in the <a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fjournals.sagepub.com%2Fdoi%2F10.1177%2F02698811261464988&amp;esheet=54570833&amp;newsitemid=20260716248636&amp;lan=en-US&amp;anchor=Journal+of+Psychopharmacology&amp;index=1&amp;md5=19442c914139081cfdfd97e83c2c5725" shape="rect">Journal of Psychopharmacology</a></b> </li> </ul> <p> LONDON &amp; NEW YORK--(BUSINESS WIRE)-- Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental health, today announced the publication of a post-hoc analysis of support methods used in an open-label Phase 2 study of investigational COMP360 synthetic psilocybin treatment in patients with post-traumatic stress disorder http://www.streetinsider.com/Press+Releases/Compass+Pathways+Announces+Publication+of+Post-Hoc+Analysis+Demonstrating+Distinction+of+COMP360+Trial+Monitoring+%26amp%3B+Support+from+Psychotherapy/26776210.html Thu, 16 Jul 2026 06:35:00 -0400 A.50216310 CMPS O.29029261 O.47928049 http://www.streetinsider.com/Press+Releases/Compass+Pathways+Announces+Publication+of+Post-Hoc+Analysis+Demonstrating+Distinction+of+COMP360+Trial+Monitoring+%26amp%3B+Support+from+Psychotherapy/26776210.html <ul class="bwlistdisc"> <li> <b>Post-hoc analysis of support methods used in an open-label Phase 2 COMP360 study showed monitoring and support provided during treatment administration sessions were minimal, non-directive and distinct from conventional conceptions of psychotherapy</b> </li> </ul><ul class="bwlistdisc"> <li> <b>Findings published in the <a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fjournals.sagepub.com%2Fdoi%2F10.1177%2F02698811261464988&amp;esheet=54570833&amp;newsitemid=20260716248636&amp;lan=en-US&amp;anchor=Journal+of+Psychopharmacology&amp;index=1&amp;md5=19442c914139081cfdfd97e83c2c5725" shape="rect">Journal of Psychopharmacology</a></b> </li> </ul> <p> LONDON &amp; NEW YORK--(BUSINESS WIRE)-- Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental health, today announced the publication of a post-hoc analysis of support methods used in an open-label Phase 2 study of investigational COMP360 synthetic psilocybin treatment in patients with post-traumatic stress disorder http://www.streetinsider.com/Press+Releases/Compass+Pathways+Announces+Publication+of+Post-Hoc+Analysis+Demonstrating+Distinction+of+COMP360+Trial+Monitoring+%26amp%3B+Support+from+Psychotherapy/26776210.html Thu, 16 Jul 2026 06:35:00 -0400 A.50216310 CMPS O.29029261 O.47928049 http://www.streetinsider.com/Business+Wire/Compass+Pathways+Announces+Publication+of+Post-Hoc+Analysis+Demonstrating+Distinction+of+COMP360+Trial+Monitoring+%26amp%3B+Support+from+Psychotherapy/26776210.html <ul class="bwlistdisc"> <li> <b>Post-hoc analysis of support methods used in an open-label Phase 2 COMP360 study showed monitoring and support provided during treatment administration sessions were minimal, non-directive and distinct from conventional conceptions of psychotherapy</b> </li> </ul><ul class="bwlistdisc"> <li> <b>Findings published in the <a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fjournals.sagepub.com%2Fdoi%2F10.1177%2F02698811261464988&amp;esheet=54570833&amp;newsitemid=20260716248636&amp;lan=en-US&amp;anchor=Journal+of+Psychopharmacology&amp;index=1&amp;md5=19442c914139081cfdfd97e83c2c5725" shape="rect">Journal of Psychopharmacology</a></b> </li> </ul> <p> LONDON &amp; NEW YORK--(BUSINESS WIRE)-- Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental health, today announced the publication of a post-hoc analysis of support methods used in an open-label Phase 2 study of investigational COMP360 synthetic psilocybin treatment in patients with post-traumatic stress disorder http://www.streetinsider.com/Business+Wire/Compass+Pathways+Announces+Publication+of+Post-Hoc+Analysis+Demonstrating+Distinction+of+COMP360+Trial+Monitoring+%26amp%3B+Support+from+Psychotherapy/26776210.html Thu, 16 Jul 2026 06:35:00 -0400 A.50216310 CMPS O.29029261 O.47928049 http://www.streetinsider.com/Business+Wire/Compass+Pathways+Announces+Publication+of+Post-Hoc+Analysis+Demonstrating+Distinction+of+COMP360+Trial+Monitoring+%26amp%3B+Support+from+Psychotherapy/26776210.html <ul class="bwlistdisc"> <li> <b>Post-hoc analysis of support methods used in an open-label Phase 2 COMP360 study showed monitoring and support provided during treatment administration sessions were minimal, non-directive and distinct from conventional conceptions of psychotherapy</b> </li> </ul><ul class="bwlistdisc"> <li> <b>Findings published in the <a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fjournals.sagepub.com%2Fdoi%2F10.1177%2F02698811261464988&amp;esheet=54570833&amp;newsitemid=20260716248636&amp;lan=en-US&amp;anchor=Journal+of+Psychopharmacology&amp;index=1&amp;md5=19442c914139081cfdfd97e83c2c5725" shape="rect">Journal of Psychopharmacology</a></b> </li> </ul> <p> LONDON &amp; NEW YORK--(BUSINESS WIRE)-- Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental health, today announced the publication of a post-hoc analysis of support methods used in an open-label Phase 2 study of investigational COMP360 synthetic psilocybin treatment in patients with post-traumatic stress disorder http://www.streetinsider.com/Business+Wire/Compass+Pathways+Announces+Publication+of+Post-Hoc+Analysis+Demonstrating+Distinction+of+COMP360+Trial+Monitoring+%26amp%3B+Support+from+Psychotherapy/26776210.html Thu, 16 Jul 2026 06:35:00 -0400 A.50216310 CMPS O.29029261 O.47928049 http://www.streetinsider.com/Business+Wire/Compass+Pathways+Announces+Publication+of+Post-Hoc+Analysis+Demonstrating+Distinction+of+COMP360+Trial+Monitoring+%26amp%3B+Support+from+Psychotherapy/26776210.html <ul class="bwlistdisc"> <li> <b>Post-hoc analysis of support methods used in an open-label Phase 2 COMP360 study showed monitoring and support provided during treatment administration sessions were minimal, non-directive and distinct from conventional conceptions of psychotherapy</b> </li> </ul><ul class="bwlistdisc"> <li> <b>Findings published in the <a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fjournals.sagepub.com%2Fdoi%2F10.1177%2F02698811261464988&amp;esheet=54570833&amp;newsitemid=20260716248636&amp;lan=en-US&amp;anchor=Journal+of+Psychopharmacology&amp;index=1&amp;md5=19442c914139081cfdfd97e83c2c5725" shape="rect">Journal of Psychopharmacology</a></b> </li> </ul> <p> LONDON &amp; NEW YORK--(BUSINESS WIRE)-- Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental health, today announced the publication of a post-hoc analysis of support methods used in an open-label Phase 2 study of investigational COMP360 synthetic psilocybin treatment in patients with post-traumatic stress disorder http://www.streetinsider.com/Business+Wire/Compass+Pathways+Announces+Publication+of+Post-Hoc+Analysis+Demonstrating+Distinction+of+COMP360+Trial+Monitoring+%26amp%3B+Support+from+Psychotherapy/26776210.html Thu, 16 Jul 2026 06:35:00 -0400 A.50216310 CMPS O.29029261 O.47928049 http://www.streetinsider.com/Business+Wire/Compass+Pathways+Announces+Publication+of+Post-Hoc+Analysis+Demonstrating+Distinction+of+COMP360+Trial+Monitoring+%26amp%3B+Support+from+Psychotherapy/26776210.html <ul class="bwlistdisc"> <li> <b>Post-hoc analysis of support methods used in an open-label Phase 2 COMP360 study showed monitoring and support provided during treatment administration sessions were minimal, non-directive and distinct from conventional conceptions of psychotherapy</b> </li> </ul><ul class="bwlistdisc"> <li> <b>Findings published in the <a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fjournals.sagepub.com%2Fdoi%2F10.1177%2F02698811261464988&amp;esheet=54570833&amp;newsitemid=20260716248636&amp;lan=en-US&amp;anchor=Journal+of+Psychopharmacology&amp;index=1&amp;md5=19442c914139081cfdfd97e83c2c5725" shape="rect">Journal of Psychopharmacology</a></b> </li> </ul> <p> LONDON &amp; NEW YORK--(BUSINESS WIRE)-- Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental health, today announced the publication of a post-hoc analysis of support methods used in an open-label Phase 2 study of investigational COMP360 synthetic psilocybin treatment in patients with post-traumatic stress disorder http://www.streetinsider.com/Business+Wire/Compass+Pathways+Announces+Publication+of+Post-Hoc+Analysis+Demonstrating+Distinction+of+COMP360+Trial+Monitoring+%26amp%3B+Support+from+Psychotherapy/26776210.html Thu, 16 Jul 2026 06:35:00 -0400 A.50216310 CMPS O.29029261 O.47928049 http://www.streetinsider.com/General+News/FDA+sets+public+hearing+on+psychedelics+for+September+14%2C+Jefferies+sees+FDA+willing+to+move+on+COMP360/26761798.html <p>Investing.com -- The Food and Drug Administration will hold a public hearing on September 14 to discuss issues related to psychedelic drugs in supervised and supportive settings, according to Jefferies.</p><p>The hearing will run from 12:30 p.m. to 4:30 p.m. Eastern Time and will allow the public to submit comments. A presiding officer will conduct the hearing alongside FDA panelists from the Center for Drug Evaluation and Research and federal partner panelists.</p><p>The FDA released final guidance on psychedelic drug development, focusing on generating interpretable efficacy data. The guidance includes expanded recommendations to reduce bias and improve trial integrity.</p><p>The agency outlined several http://www.streetinsider.com/General+News/FDA+sets+public+hearing+on+psychedelics+for+September+14%2C+Jefferies+sees+FDA+willing+to+move+on+COMP360/26761798.html Mon, 13 Jul 2026 13:04:03 -0400 CMPS http://www.streetinsider.com/Analyst+Comments/TD+Cowen+Reiterates+Buy+Rating+on+Compass+Pathways+%28CMPS%29/26759291.html <p>TD Cowen analyst Ritu Baral reiterated a Buy rating and $29.00 price target on Compass Pathways (NASDAQ: CMPS).</p><p>The analyst comments "KOL feedback and a recent OL study of psilocybin/25 mg COMP360 in TRD pts w/ chronic suicidal ideation suggest no treatment-emergent suicidality signal. COMP360 drove rapid reductions in MSSI scores, with 75% achieving an anti-suicidal response at wk 3 and 35% remaining in remission at wk 12. Data suggest MSSI benefit may wane in some pts over time, highlighting the need for careful monitoring. Given recent investor concerns on the single completed suicide reported in CMPS' 26-week Ph3 repeat-dose '006 http://www.streetinsider.com/Analyst+Comments/TD+Cowen+Reiterates+Buy+Rating+on+Compass+Pathways+%28CMPS%29/26759291.html Mon, 13 Jul 2026 06:26:44 -0400 CMPS http://www.streetinsider.com/Analyst+Comments/H.C.+Wainwright+Reiterates+Buy+Rating+on+Compass+Pathways+%28CMPS%29/26749840.html <p>H.C. Wainwright analyst Patrick Trucchio reiterated a Buy rating and $70.00 price target on Compass Pathways (NASDAQ: CMPS).</p><p>The analyst commented: "On July 7, COMPASS hosted a webcast reviewing the 26-week (Part B) results from COMP006, the second and larger of its two pivotal Phase 3 trials of COMP360 synthetic psilocybin in treatment-resistant depression (TRD) (link to webcast and slides). The key new incremental data include: (1) 39% of patients in the 25 mg arm achieved a clinically meaningful ≥25% reduction on Montgomery-Åsberg Depression Rating Scale (MADRS) by Week 6, and, on average, maintained it through at least Week 26; (2) http://www.streetinsider.com/Analyst+Comments/H.C.+Wainwright+Reiterates+Buy+Rating+on+Compass+Pathways+%28CMPS%29/26749840.html Thu, 09 Jul 2026 06:49:35 -0400 CMPS http://www.streetinsider.com/Upgrades/Evercore+ISI+Upgrades+Compass+Pathways+%28CMPS%29+to+Outperform/26745502.html <p>Evercore ISI analyst Josh Schimmer upgraded Compass Pathways (NASDAQ: CMPS) from In Line to Outperform with a price target of $21.00.</p><p>For an analyst ratings summary and ratings history on Compass Pathways <a href="http://www.streetinsider.com/rating_history.php?q=CMPS">click here</a>. For more ratings news on Compass Pathways <a href="http://www.streetinsider.com/stock_lookup_news.php?q=CMPS&amp;type=analyst">click here</a>.</p><p>Shares of Compass Pathways closed at $12.99 yesterday.</p> http://www.streetinsider.com/Upgrades/Evercore+ISI+Upgrades+Compass+Pathways+%28CMPS%29+to+Outperform/26745502.html Wed, 08 Jul 2026 09:42:13 -0400 CMPS http://www.streetinsider.com/Analyst+Comments/Canaccord+Reiterates+Buy+Rating+on+Compass+Pathways+%28CMPS%29/26744027.html <p>Canaccord analyst Sumant Kulkarni reiterated a Buy rating and $20.00 price target on Compass Pathways (NASDAQ: CMPS).</p><p>The analyst commented: "This morning, CMPS reported what we view as robust durability data from Part B of COMP006, its second Phase 3 trial for COMP360 for treatment-resistant depression (TRD). Specifically, 39% of patients achieved a clinically-meaningful response after two doses of COMP360 at 26 weeks vs. 25% in Part B of COMP005, which involved a single dose. In addition, 28% of responders went into remission in the treatment interval. In fact, we see the results as more representative of scenarios we had cited http://www.streetinsider.com/Analyst+Comments/Canaccord+Reiterates+Buy+Rating+on+Compass+Pathways+%28CMPS%29/26744027.html Wed, 08 Jul 2026 06:49:39 -0400 CMPS http://www.streetinsider.com/Analyst+PT+Change/Compass+Pathways+%28CMPS%29+PT+Raised+to+%2421+at+Stifel/26742216.html <p>Stifel analyst Paul Matteis raised the price target on Compass Pathways (NASDAQ: CMPS) to $21.00 (from $14.00) while maintaining a Buy rating.</p><p>The analyst comments "We're raising our Target Price to $21 following 6-month blinded durability data from the '006 study of COMP360 (LINK) which affirms the added clinical benefit of a seconddose of COMP360 and supports a drug profile in TRD that has meaningful advantages vs. Spravato, which is expected to be a $3B-$4B peak product. We think there's room for multiple winners in the emerging psychedelic class, and expect significant patient demand for '360, expected to launch 1H27 following http://www.streetinsider.com/Analyst+PT+Change/Compass+Pathways+%28CMPS%29+PT+Raised+to+%2421+at+Stifel/26742216.html Tue, 07 Jul 2026 16:33:22 -0400 CMPS http://www.streetinsider.com/Analyst+Comments/Compass+Pathways+%28CMPS%29+PT+Raised+to+%2421+at+Stifel/26742216.html <p>Stifel analyst Paul Matteis raised the price target on Compass Pathways (NASDAQ: CMPS) to $21.00 (from $14.00) while maintaining a Buy rating.</p><p>The analyst comments "We're raising our Target Price to $21 following 6-month blinded durability data from the '006 study of COMP360 (LINK) which affirms the added clinical benefit of a seconddose of COMP360 and supports a drug profile in TRD that has meaningful advantages vs. Spravato, which is expected to be a $3B-$4B peak product. We think there's room for multiple winners in the emerging psychedelic class, and expect significant patient demand for '360, expected to launch 1H27 following http://www.streetinsider.com/Analyst+Comments/Compass+Pathways+%28CMPS%29+PT+Raised+to+%2421+at+Stifel/26742216.html Tue, 07 Jul 2026 16:33:22 -0400 CMPS http://www.streetinsider.com/Analyst+Comments/TD+Cowen+on+Compass+Pathways+%28CMPS%29%3A+%27We+think+DEA+reclassification+to+schedule+3+after+approval+is+likely%27/26741647.html <p>TD Cowen analyst Ritu Baral reiterated a Buy rating and $29.00 price target on Compass Pathways (NASDAQ: CMPS).</p><p>The analyst comments "Our Take: Overall, we view the 26-week '006 data as directionally stronger than study '005 across both initial remission & durability-driven conversion to remission, reinforcing our view of dose-dependent benefit & that a two-dose induction regimen will likely emerge as the recommended treatment paradigm for most TRD pts. While mgmt noted a subset of pts who achieve a particularly robust response after the initial dose may not require a 2nd one, we believe the totality of the data supports label http://www.streetinsider.com/Analyst+Comments/TD+Cowen+on+Compass+Pathways+%28CMPS%29%3A+%27We+think+DEA+reclassification+to+schedule+3+after+approval+is+likely%27/26741647.html Tue, 07 Jul 2026 15:53:22 -0400 CMPS http://www.streetinsider.com/Analyst+Comments/Wolfe+Research+on+Compass+Pathways+%28CMPS%29%3A+%27we+expect+the+stock+to+regain+strong+momentum+after+this+pullback%27/26741641.html <p>Wolfe Research analyst Rudy Li reiterated an Outperform rating and $18.00 price target on Compass Pathways (NASDAQ: CMPS).</p><p>The analyst comments "COMP006's durable 26-week data, improved responder/remission rates, and clean safety profile keep the NDA/1H27 launch on track — We view today's pullback as a sell-the-news overreaction and an attractive entry point. Despite genuinely positive, consistent durability and safety data, CMPS fell ~10% intraday alongside a volatile XBI — a classic "sell-the-news" reaction after shares ran up toward 52-week highs of $15 range in late June. We continue to like this name as the underlying regulatory/commercial trajectory looks intact. And we http://www.streetinsider.com/Analyst+Comments/Wolfe+Research+on+Compass+Pathways+%28CMPS%29%3A+%27we+expect+the+stock+to+regain+strong+momentum+after+this+pullback%27/26741641.html Tue, 07 Jul 2026 15:52:10 -0400 CMPS http://www.streetinsider.com/Hot+Comments/Wolfe+Research+on+Compass+Pathways+%28CMPS%29%3A+%27we+expect+the+stock+to+regain+strong+momentum+after+this+pullback%27/26741641.html <p>Wolfe Research analyst Rudy Li reiterated an Outperform rating and $18.00 price target on Compass Pathways (NASDAQ: CMPS).</p><p>The analyst comments "COMP006's durable 26-week data, improved responder/remission rates, and clean safety profile keep the NDA/1H27 launch on track — We view today's pullback as a sell-the-news overreaction and an attractive entry point. Despite genuinely positive, consistent durability and safety data, CMPS fell ~10% intraday alongside a volatile XBI — a classic "sell-the-news" reaction after shares ran up toward 52-week highs of $15 range in late June. We continue to like this name as the underlying regulatory/commercial trajectory looks intact. And we http://www.streetinsider.com/Hot+Comments/Wolfe+Research+on+Compass+Pathways+%28CMPS%29%3A+%27we+expect+the+stock+to+regain+strong+momentum+after+this+pullback%27/26741641.html Tue, 07 Jul 2026 15:52:10 -0400 CMPS http://www.streetinsider.com/Analyst+Comments/Oppenheimer+on+Compass+Pathways+%28CMPS%29%3A+%27Reinforced+Durability+Strengthens+Launch+Prospects%27/26740783.html <p>Oppenheimer analyst Francois Brisebois reiterated an Outperform rating and $20.00 price target on Compass Pathways (NASDAQ: CMPS).</p><p>The analyst comments "We view the Ph3 COMP006 26-week data as reinforcing the durable efficacy profile of COMP360 (psilocybin), representing a transformative approach for the ~4M addressable TRD patients. CMPS previously observed 26-week durability in the Ph3 COMP005 study, and now shows consistent results for this second pivotal study with ~30% of responders achieving remission following re-treatment in the Part-B portion. We believe these data strengthen the overall dataset that could support the first-ever FDA approval for a classical psychedelic while informing real-world expectations. http://www.streetinsider.com/Analyst+Comments/Oppenheimer+on+Compass+Pathways+%28CMPS%29%3A+%27Reinforced+Durability+Strengthens+Launch+Prospects%27/26740783.html Tue, 07 Jul 2026 12:11:40 -0400 CMPS http://www.streetinsider.com/Hot+Comments/Oppenheimer+on+Compass+Pathways+%28CMPS%29%3A+%27Reinforced+Durability+Strengthens+Launch+Prospects%27/26740783.html <p>Oppenheimer analyst Francois Brisebois reiterated an Outperform rating and $20.00 price target on Compass Pathways (NASDAQ: CMPS).</p><p>The analyst comments "We view the Ph3 COMP006 26-week data as reinforcing the durable efficacy profile of COMP360 (psilocybin), representing a transformative approach for the ~4M addressable TRD patients. CMPS previously observed 26-week durability in the Ph3 COMP005 study, and now shows consistent results for this second pivotal study with ~30% of responders achieving remission following re-treatment in the Part-B portion. We believe these data strengthen the overall dataset that could support the first-ever FDA approval for a classical psychedelic while informing real-world expectations. http://www.streetinsider.com/Hot+Comments/Oppenheimer+on+Compass+Pathways+%28CMPS%29%3A+%27Reinforced+Durability+Strengthens+Launch+Prospects%27/26740783.html Tue, 07 Jul 2026 12:11:40 -0400 CMPS http://www.streetinsider.com/Analyst+PT+Change/Compass+Pathways+%28CMPS%29+PT+Raised+to+%2425+at+BTIG%2C+%27executed+nearly+flawlessly+on+everything+within+its+control%27/26740779.html <p>BTIG analyst Madison El-Saadi raised the price target on Compass Pathways (NASDAQ: CMPS) to $25.00 (from $14.00) while maintaining a Buy rating.</p><p>The analyst comments "This was bound to happen if enough patients were treated and today's call disclosed one suspected completed suicide in the 25mg arm, deemed not related to treatment by the investigator based on specific circumstances and timing. All these qualifications suggest the event has already triggered extensive discussion, and we expect the discussion to continue. Suicide is part of the TRD landscape and that unfortunate reality was also driven home by today's readout as one event of http://www.streetinsider.com/Analyst+PT+Change/Compass+Pathways+%28CMPS%29+PT+Raised+to+%2425+at+BTIG%2C+%27executed+nearly+flawlessly+on+everything+within+its+control%27/26740779.html Tue, 07 Jul 2026 12:10:45 -0400 CMPS http://www.streetinsider.com/Analyst+Comments/Compass+Pathways+%28CMPS%29+PT+Raised+to+%2425+at+BTIG%2C+%27executed+nearly+flawlessly+on+everything+within+its+control%27/26740779.html <p>BTIG analyst Madison El-Saadi raised the price target on Compass Pathways (NASDAQ: CMPS) to $25.00 (from $14.00) while maintaining a Buy rating.</p><p>The analyst comments "This was bound to happen if enough patients were treated and today's call disclosed one suspected completed suicide in the 25mg arm, deemed not related to treatment by the investigator based on specific circumstances and timing. All these qualifications suggest the event has already triggered extensive discussion, and we expect the discussion to continue. Suicide is part of the TRD landscape and that unfortunate reality was also driven home by today's readout as one event of http://www.streetinsider.com/Analyst+Comments/Compass+Pathways+%28CMPS%29+PT+Raised+to+%2425+at+BTIG%2C+%27executed+nearly+flawlessly+on+everything+within+its+control%27/26740779.html Tue, 07 Jul 2026 12:10:45 -0400 CMPS http://www.streetinsider.com/Hot+Comments/Compass+Pathways+%28CMPS%29+PT+Raised+to+%2425+at+BTIG%2C+%27executed+nearly+flawlessly+on+everything+within+its+control%27/26740779.html <p>BTIG analyst Madison El-Saadi raised the price target on Compass Pathways (NASDAQ: CMPS) to $25.00 (from $14.00) while maintaining a Buy rating.</p><p>The analyst comments "This was bound to happen if enough patients were treated and today's call disclosed one suspected completed suicide in the 25mg arm, deemed not related to treatment by the investigator based on specific circumstances and timing. All these qualifications suggest the event has already triggered extensive discussion, and we expect the discussion to continue. Suicide is part of the TRD landscape and that unfortunate reality was also driven home by today's readout as one event of http://www.streetinsider.com/Hot+Comments/Compass+Pathways+%28CMPS%29+PT+Raised+to+%2425+at+BTIG%2C+%27executed+nearly+flawlessly+on+everything+within+its+control%27/26740779.html Tue, 07 Jul 2026 12:10:45 -0400 CMPS